Koninklijke Philips N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHG research report →
Price Chart
About the company
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology.
- CEO
- Roy W. O. Jakobs
- IPO
- 1980
- Employees
- 66,401
- HQ
- Amsterdam, NH, NL
Get TickerSpark's AI analysis on PHG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.87B
- P/E
- 26.96
- Fwd P/E
- 17.22
- PEG
- 0.05
- P/S
- 1.50
- P/B
- 2.29
- EV/EBITDA
- 10.14
- Div Yield
- 3.13%
- Gross Margin
- 46.43%
- Op Margin
- 10.93%
- Net Margin
- 5.39%
- ROE
- 8.44%
- ROIC
- 6.58%
Latest fiscal year · YoY change
- Revenue
- $17.83B-1.0%
- Gross Profit
- $8.06B+3.7%
- Op Income
- $1.42B
- Net Income
- $895.00M+227.5%
- EPS
- $0.95+226.7%
- OCF Growth
- -25.9%
- FCF Growth
- +0.0%
- 52W High
- $33.44
- 52W Low
- $23.62
- 50D MA
- $26.51
- 200D MA
- $27.25
- Beta
- 0.92
- RSI (14)
- 51
- Avg Volume
- 1.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Philips reported solid Q3 execution with 3% comparable sales growth, 13% adjusted EBITA margin, strong cash flow, and improved order momentum, while reiterating full-year guidance and highlighting progress on the Respironics settlement.· November 3, 2026
- Order intake rose 8%, with equipment orders up 8% and D&T orders approaching 20% growth, signaling healthier pipeline momentum.
- Comparable sales grew about 3%, led by Personal Health at 8% and Connected Care at 5%, while Diagnosis & Treatment was broadly flat due to ultrasound phasing and lower China sales.
- Adjusted EBITA margin expanded 70 basis points to 13%, helped by gross margin improvement, productivity savings, and innovation mix.
- Free cash flow was EUR 384 million, up from EUR 172 million a year ago; net debt fell to EUR 5.4 billion and leverage declined to 1.7x.
- Philips recorded a EUR 288 million provision tied to an agreement in principle with the U.S. DOJ on Respironics, but kept full-year guidance unchanged.
Q3 comparable sales growth was approximately 3%. Adjusted EBITA margin increased 70 basis points year over year to 13%. Adjusted EPS was EUR 0.40, up more than 10% year over year. Free cash flow was EUR 384 million versus EUR 172 million in Q3 last year. Order intake grew 8%, and equipment order intake also grew 8%. Year-to-date, order intake is up 4%, comparable sales growth is 3.5%, and underlying adjusted EBITA margin has expanded 30 basis points to 11.5% despite inflation and tariffs. Charlotte Hanneman also said net financial expenses were EUR 42 million in the quarter and now expected full year net financial expenses are approximately EUR 230 million. The company recorded a EUR 288 million provision related to the Respironics DOJ settlement. For full year 2026, Philips reiterated comparable sales growth of 3% to 4.5%, adjusted EBITA margin of 13.5% to 14%, and free cash flow of EUR 1.5 billion to EUR 1.7 billion. By segment, it expects D&T at the upper end of the low single-digit range, Connected Care at 3% to 4.5%, and Personal Health at the lower end of high single-digit growth.
Roy Jakobs emphasized that the quarter showed continued progress on Philips’ plan, with strong order momentum, sales growth, and margin expansion despite a difficult environment. He repeatedly pointed to innovation-led growth in D&T and Personal Health, saying the company is gaining traction with customers, rebuilding the Precision Diagnosis order book, and winning larger platform-based deals in North America and elsewhere. His tone was confident but measured, with an emphasis on disciplined execution, patient safety, supply chain resilience, and staying on track for the company’s medium-term mid-single-digit sales CAGR and mid-teen margin ambition by 2028.
Charlotte Hanneman focused on margin conversion, cash, and guidance discipline. She said Q3 adjusted EBITA margin of 13% was ahead of expectations, with year-to-date margin up 30 basis points and productivity savings of EUR 170 million in Q3 and EUR 427 million year to date, on track for the EUR 1.5 billion target by end-2028. She also highlighted a strong cash position of EUR 2.8 billion, net debt of EUR 5.4 billion, and leverage at 1.7x, plus a EUR 650 million EU Green Bond issued in August on competitive terms. On the outlook, she reiterated full-year comparable sales, margin, and free cash flow guidance and noted the outlook assumes payment of the U.S. DOJ settlement in Q1 2027 and excludes other Respironics proceedings.
Analysts pressed management on whether Q4 margin improvement is still achievable despite inflation, and Philips said the main supports remain operating leverage, innovation-driven gross margin, productivity, and some tariff easing. Questions on D&T orders versus sales were answered by saying the order book has now been rebuilt, ultrasound timing should support Q4 and 2027, and Precision Diagnosis is at a turning point with stronger conversion ahead. Analysts also asked about Connected Care order timing, China pricing pressure from centralized procurement, buybacks, and inventory; management said the slower monitoring conversion reflects larger, more complex deals rather than lost share, China remains cautious due to procurement and pricing, buybacks are a fourth-priority capital allocation item, and inventory rose mainly due to Personal Health growth preparation and prebuys for inflation risk.
The bull case from this call is that Philips is converting innovation and platform wins into better orders, higher margins, and stronger cash generation. Management also sounded more confident about D&T momentum, especially Precision Diagnosis and monitoring, and said the company is still on track for its 2026 and 2028 targets. The DOJ progress reduces a major uncertainty, and the balance sheet appears more resilient than a year ago.
The main risks discussed were persistent cost inflation, tariff uncertainty, China softness, and timing volatility in ultrasound and monitoring orders. Management also flagged that some D&T sales are being delayed into Q4 and early 2027, and that monitoring contracts are getting larger and longer to close. The Respironics situation is not fully resolved, since other related proceedings remain excluded from guidance and FDA timing for a U.S. return to market is still uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 968.43M
- Float Shares
- 967.43M
of shares held by institutions
377 13F filers
Congressional trading
Senate and House stock disclosures for PHG, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Earl BlumenauerHouse · OR03 | Buy | Feb 12, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 2, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Sep 2, 22 | Filing → |
| Earl BlumenauerHouse · OR03 | Buy | Jul 27, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 5, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 5, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Jan 18, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Jan 18, 22 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Dec 14, 21 | Filing → |
| Katherine M. ClarkHouse · MA05 | Sell | Sep 16, 21 | Filing → |
| Katherine M. ClarkHouse · MA05 | Buy | Nov 5, 20 | Filing → |
| Dean PhillipsHouse · MN03 | Buy | Jun 8, 20 | Filing → |
| Dean PhillipsHouse · MN03 | Buy | Apr 22, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mondrian Investment Partners Ltd | 7.89M | ▼ 181.75K |
| Dimensional Fund Advisors LP | 4.41M | ▲ 67.17K |
| Fiduciary Management Inc | 3.29M | ▼ 166.91K |
| Causeway Capital Management LLC | 2.99M | ▼ 67.42K |
| Morgan Stanley | 2.76M | ▼ 174.32K |
| Fmr LLC | 2.69M | ▲ 36.15K |
| Brandes Investment Partners, LP | 2.21M | ▲ 221.33K |
| Northern Trust Corp | 2.09M | ▲ 18.73K |
| Blackrock, Inc. | 1.91M | ▼ 85.45K |
| Envestnet Asset Management Inc | 1.30M | ▲ 25.68K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 944.31K | ▼ 32.93K |
| Goldman Sachs Group Inc | 911.85K | ▼ 161.89K |
Held by 23 ETFs
Biggest fund positions in PHG by dollar value.
Our PHG coverage
Recent articles, reports, and earnings notes.
No research on PHG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHG report →Philips Unveils Skylight Device Manager to Boost Ultrasound Efficiency
zacks.com · Nov 19
Philips introduces Advanced Image Insights for advanced visualization and AI orchestration
globenewswire.com · Nov 19
Philips introduces Skylight Device Manager to turn ultrasound data into operational intelligence
globenewswire.com · Nov 18
Here's Why You Should Retain PHG Stock in Your Portfolio for Now
zacks.com · Nov 16
Philips to nominate Dick Boer, Laurence Debroux and Todd Brinton to its Supervisory Board at the 2027 Annual General Meeting of Shareholders (AGM)
globenewswire.com · Nov 16
Philips Avent Launches New Natural Response Glass Baby Bottle with a Lighter, Stronger Design
prnewswire.com · Nov 9
Philips: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 6
What Koninklijke Philips (PHG) Said on Its Q3 Earnings Call
defenseworld.net · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.